Drug Patents owned by Xspire Pharma

1. List of Zontivity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713999 XSPIRE PHARMA Thrombin receptor antagonists
May, 2024

(11 months from now)

US7304078 XSPIRE PHARMA Thrombin receptor antagonists
Dec, 2027

(4 years from now)

Do you want to check out ZONTIVITY patents from before 2022?

Drugs and Companies using VORAPAXAR SULFATE ingredient

Market Authorisation Date: 08 May, 2014

Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad); Reduction of thrombotic cardiovascular events

Dosage: TABLET;ORAL

More Information on Dosage

ZONTIVITY family patents

18

United States

12

European Union

8

Japan

6

Australia

6

Korea, Republic of

6

Norway

6

China

5

Canada

5

Spain

5

Russia

5

Hong Kong

5

Argentina

5

Brazil

5

South Africa

5

Taiwan

4

Ecuador

4

Israel

4

New Zealand

4

Peru

4

Malaysia

4

Austria

4

Mexico

4

Germany

3

Denmark

3

Cyprus

3

Portugal

3

Slovenia

2

Singapore

2

Poland

1

Colombia

1

Luxembourg

1

Netherlands

1

Chile

1

Slovakia

1

Czech Republic

1

Hungary

1

Lithuania

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in